Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by DJDawgon Apr 05, 2022 1:50pm
263 Views
Post# 34577485

patient tracker

patient tracker
Hell all,

What a strange way to update the data.

It is very hard to make the optimized data set make sense at this point because it jumped from 18 patients to 27 patients but we don't really know when they got the do-over treatment. I will keep trying to make sense but not much luck  yet.

Here is the updated patient tracker for 38 patients.

https://postimg.cc/JtpBS6DJ

I like how a good chunk of the 90 days CR move into 180 day still being CR. Of 15 CR at 90 days, 12 stay CR.

I did not make this from anything other than the releases so there are a few guesses but the numbers add up to match the new release April 5 for ALL 38 patients. I cannot make sense of the optimized table to date.

GLTA
<< Previous
Bullboard Posts
Next >>